Baltimore, MD – According to filings with the U.S. Securities and Exchange Commission, Personal Genome Diagnostics is raising $98,295,724.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Megan Bailey played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Personal Genome Diagnostics

Personal Genome Diagnostics (PGDx) is Empowering the Fight Against Cancer by unlocking actionable information from the genome. We are developing an innovative portfolio of regulated tissue-based and non-invasive liquid biopsy genomic products for laboratories worldwide. Built upon our strong academic foundation with leadership in genomics, we have assembled experts in product development, regulatory, operations and commercialization to deliver products that bring precision medicine to more patients globally.

To learn more about Personal Genome Diagnostics, visit http://www.personalgenome.com/

Contact:
Megan Bailey, Chief Executive Officer
443-602-8833
mbailey@personalgenome.com
https://www.linkedin.com/in/megandempseybailey/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved